AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on November 11, 2024, by Aytu BioPharma, Inc. (Nasdaq: AYTU). The filing primarily addresses significant changes in executive leadership and corporate governance, alongside a reference to the upcoming announcement of fiscal 2025 first-quarter operational and financial results scheduled for November 13, 2024.
Key Financial Metrics
The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the current period. These metrics are referenced as being contained in a press release issued on November 13, 2024, which is attached as Exhibit 99.1 but not detailed within the body of this 8-K.
Material Changes and Executive Actions
- Termination of CFO: Mark K. Oki was terminated as Chief Financial Officer on November 11, 2024. He will consult through December 1, 2024.
- Separation Package: Mr. Oki is entitled to a separation payment of $499,590 paid over 12 months, payment for accrued unused personal time off, COBRA coverage for up to 12 months, and acceleration of unvested options or restricted stock.
- Appointment of New CFO: Ryan Selhorn was appointed Chief Financial Officer, Corporate Secretary, and Treasurer on November 11, 2024. He previously served as Executive Vice President, Finance and Business Optimization.
- New CFO Compensation: Mr. Selhorn's employment agreement includes a $400,000 annual base salary, a target bonus of 40% of base salary, and a restricted stock grant of 14,000 shares.
- Board Leadership Change: On November 6, 2024, the Board separated the roles of Chairman and CEO. John A. Donofrio, Jr. was appointed Chairman of the Board, replacing Joshua R. Disbrow.
Guidance, Outlook, and Risks
The Company scheduled a conference call for November 13, 2024, to discuss fiscal 2025 first-quarter results. The filing notes that the press release containing these results and the leadership changes shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. No specific forward-looking guidance or risk factors are detailed in this text beyond the standard disclosure regarding the leadership transition.
Investor Verification Checklist
- Review the November 13, 2024 press release (Exhibit 99.1) for specific Q1 2025 financial results and operational metrics.
- Examine the full Separation Agreement with Mark K. Oki (to be filed in the Q4 2024 Form 10-Q) for complete terms regarding the $499,590 payout and stock acceleration.
- Review the Amended and Restated Employment Agreement with Ryan Selhorn (Exhibit 10.1) for detailed vesting schedules and severance triggers.
- Confirm the impact of the CFO transition on the Company's financial reporting timeline and internal controls.